RATIONALE: The etiology of schistosomiasis-associated pulmonary arterial hypertension (PAH), a major cause of PAH worldwide, is poorly understood. Schistosoma mansoni exposure results in prototypical type-2 inflammation. Furthermore, transforming growth factor (TGF)-β signaling is required for experimental pulmonary hypertension (PH) caused by Schistosoma exposure. OBJECTIVES: We hypothesized type-2 inflammation driven by IL-4 and IL-13 is necessary for Schistosoma-induced TGF-β-dependent vascular remodeling. METHODS: Wild-type, IL-4(-/-), IL-13(-/-), and IL-4(-/-)IL-13(-/-) mice (C57BL6/J background) were intraperitoneally sensitized and intravenously challenged with S. mansoni eggs to induce experimental PH. Right ventricular catheterization was then performed, followed by quantitative analysis of the lung tissue. Lung tissue from patients with schistosomiasis-associated and connective tissue disease-associated PAH was also systematically analyzed. MEASUREMENTS AND MAIN RESULTS: Mice with experimental Schistosoma-induced PH had evidence of increased IL-4 and IL-13 signaling. IL-4(-/-)IL-13(-/-) mice, but not single knockout IL-4(-/-) or IL-13(-/-) mice, were protected from Schistosoma-induced PH, with decreased right ventricular pressures, pulmonary vascular remodeling, and right ventricular hypertrophy. IL-4(-/-)IL-13(-/-) mice had less pulmonary vascular phospho-signal transducer and activator of transcription 6 (STAT6) and phospho-Smad2/3 activity, potentially caused by decreased TGF-β activation by macrophages. In vivo treatment with a STAT6 inhibitor and IL-4(-/-)IL-13(-/-) bone marrow transplantation also protected against Schistosoma-PH. Lung tissue from patients with schistosomiasis-associated and connective tissue disease-associated PAH had evidence of type-2 inflammation. CONCLUSIONS: Combined IL-4 and IL-13 deficiency is required for protection against TGF-β-induced pulmonary vascular disease after Schistosoma exposure, and targeted inhibition of this pathway is a potential novel therapeutic approach for patients with schistosomiasis-associated PAH.
RATIONALE: The etiology of schistosomiasis-associated pulmonary arterial hypertension (PAH), a major cause of PAH worldwide, is poorly understood. Schistosoma mansoni exposure results in prototypical type-2 inflammation. Furthermore, transforming growth factor (TGF)-β signaling is required for experimental pulmonary hypertension (PH) caused by Schistosoma exposure. OBJECTIVES: We hypothesized type-2 inflammation driven by IL-4 and IL-13 is necessary for Schistosoma-induced TGF-β-dependent vascular remodeling. METHODS: Wild-type, IL-4(-/-), IL-13(-/-), and IL-4(-/-)IL-13(-/-) mice (C57BL6/J background) were intraperitoneally sensitized and intravenously challenged with S. mansoni eggs to induce experimental PH. Right ventricular catheterization was then performed, followed by quantitative analysis of the lung tissue. Lung tissue from patients with schistosomiasis-associated and connective tissue disease-associated PAH was also systematically analyzed. MEASUREMENTS AND MAIN RESULTS:Mice with experimental Schistosoma-induced PH had evidence of increased IL-4 and IL-13 signaling. IL-4(-/-)IL-13(-/-) mice, but not single knockout IL-4(-/-) or IL-13(-/-) mice, were protected from Schistosoma-induced PH, with decreased right ventricular pressures, pulmonary vascular remodeling, and right ventricular hypertrophy. IL-4(-/-)IL-13(-/-) mice had less pulmonary vascular phospho-signal transducer and activator of transcription 6 (STAT6) and phospho-Smad2/3 activity, potentially caused by decreased TGF-β activation by macrophages. In vivo treatment with a STAT6 inhibitor and IL-4(-/-)IL-13(-/-) bone marrow transplantation also protected against Schistosoma-PH. Lung tissue from patients with schistosomiasis-associated and connective tissue disease-associated PAH had evidence of type-2 inflammation. CONCLUSIONS: Combined IL-4 and IL-13 deficiency is required for protection against TGF-β-induced pulmonary vascular disease after Schistosoma exposure, and targeted inhibition of this pathway is a potential novel therapeutic approach for patients with schistosomiasis-associated PAH.
Authors: J Hu-Li; C Pannetier; L Guo; M Löhning; H Gu; C Watson; M Assenmacher; A Radbruch; W E Paul Journal: Immunity Date: 2001-01 Impact factor: 31.745
Authors: Caio J C S Fernandes; Bruno A Dias; Carlos V P Jardim; Andre Hovnanian; Susana Hoette; Luciana K Morinaga; Silvia Souza; Milena Suesada; Ana P Breda; Rogério Souza Journal: Chest Date: 2011-10-26 Impact factor: 9.410
Authors: Brian B Graham; Jacob Chabon; Liya Gebreab; Jennifer Poole; Elias Debella; Laura Davis; Takeshi Tanaka; Linda Sanders; Nina Dropcho; Angela Bandeira; R William Vandivier; Hunter C Champion; Ghazwan Butrous; Xiao-Jing Wang; Thomas A Wynn; Rubin M Tuder Journal: Circulation Date: 2013-08-19 Impact factor: 29.690
Authors: Rui He; Hye Young Kim; Juhan Yoon; Michiko K Oyoshi; Andrew MacGinnitie; Sho Goya; Eva-Jasmin Freyschmidt; Paul Bryce; Andrew N J McKenzie; Dale T Umetsu; Hans C Oettgen; Raif S Geha Journal: J Allergy Clin Immunol Date: 2009-10 Impact factor: 10.793
Authors: Y Yamaguchi; J Ono; M Masuoka; S Ohta; K Izuhara; Z Ikezawa; M Aihara; K Takahashi Journal: Br J Dermatol Date: 2013-03-07 Impact factor: 9.302
Authors: Monica G Chiaramonte; Margaret Mentink-Kane; Bruce A Jacobson; Allen W Cheever; Matthew J Whitters; Mary E P Goad; Anthony Wong; Mary Collins; Debra D Donaldson; Michael J Grusby; Thomas A Wynn Journal: J Exp Med Date: 2003-03-17 Impact factor: 14.307
Authors: Claudia Mickael; Rahul Kumar; Daniel Hernandez-Saavedra; Biruk Kassa; Linda Sanders; Dan Koyanagi; Sue Gu; Michael H Lee; Rubin M Tuder; Brian B Graham Journal: Am J Respir Cell Mol Biol Date: 2019-07 Impact factor: 6.914
Authors: Rahul Kumar; Claudia Mickael; Biruk Kassa; Linda Sanders; Daniel Hernandez-Saavedra; Daniel E Koyanagi; Sushil Kumar; Steve C Pugliese; Stacey Thomas; Jazalle McClendon; James P Maloney; William J Janssen; Kurt R Stenmark; Rubin M Tuder; Brian B Graham Journal: Cardiovasc Res Date: 2020-10-01 Impact factor: 10.787